European Project on Mendelian Forms of Parkinson’s Disease (MEFOPA)

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2010
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
    Parkinson's Disease


The European Project on Mendelian Forms of Parkinson’s Disease (MEFOPA) is a consortium that advances the basic and clinical research on rare Mendelian forms of Parkinson’s disease (PD) by identifying and validating relevant disease-related molecular pathways, drug targets, and biomarkers for disease susceptibility and progression.


MEFOPA focuses on the molecular pathways underlying inherited forms of PD with autosomal-dominant and autosomal-recessive inheritance. By integrating cellular and animal models, with the latest analytical technologies, MEFOPA aims to provide targets for novel, disease-modifying treatment strategies. In a third subproject, a European registry and biobank for patients with rare Mendelian forms of PD will also be established. Body fluids will be collected and systematically analyzed by unbiased proteomic techniques as well as by focused analysis of candidate proteins, and ex vivo cellular models will be generated, in order to allow validation of disease-related alterations detected in the models analyzed in subprojects 1 and 2.

Through this integrated, translational approach combining basic and clinical research groups, MEFOPA aims to achieve measurable progress in defining the relevant targets and readouts for disease-modifying therapies and will set the stage for rationally designed drug trials in carefully selected groups of patients and even presymptomatic mutation carriers.

The mutations in the dominant genes are thought to cause PD by a gain-of-function mechanism. SNCA- as well as most cases of LRRK2-related PD are pathologically characterized by aggregates of a-synuclein (“Lewy-pathology”). It is therefore appropriate to assume that the pathogenic mechanisms of SNCA- and LRRK2-related PD interconnect. Research on the pathogenesis of those Mendelian forms of PD is coordinated in subproject 1.

Autosomal-recessive mutations in the genes for parkin, PINK-1, and DJ1 are believed to exert their pathogenic effect because of loss of some essential protective function. There is converging evidence suggesting that dysfunction of all recessive PD genes contribute to a state of increased cellular stress because of mitochondrial dysfunction and increased burden of radical oxygen species (ROS) and that at least two of the recessive PD genes, parkin and PINK1, operate within one single pathway.  The molecular underpinnings of recessive Mendelian forms of PD will therefore also be investigated together, in subproject 2.

The findings in the basic science work packages of the first two subprojects will directly feed into subproject 3, where a European registry and biobank for patients with rare Mendelian forms of PD will be established in order to advance investigations of biomarkers.


MEFOPA is funded through the European Union Seventh Framework Programme under Project No. 241791. The European Commission contribution is €6 million. 


Points of Contact

Thomas Gasser
Project Management
University of Tübingen
Department of Medical Genetics
Calwerstr. 7
72076 Tübingen
phone: +49-7071-2972285
fax: +49-7071-295228

Sponsors & Partners

Biomedical Research Foundation of the Academy of Athens

CSS-Mendel Institute Rome

Fundació Privada Clinic per a la Recerca Biomèdica

Fundación Ilundain, San Sebastián

Institut National de la Sante et de la Recherche Medicale (INSERM)

Instituto de Medicina Molecular Lisbon

Katholieke Universiteit Leuven

Lund University

Nation and Kapodistrian University of Athens

Novartis AG

Semmelweis University Budapest, Hungary

The Chancellor, Masters and Scholars of the University of Cambridge

Trophos S.A.

United Arab Emirates University, Faculty of Medicine and Health Science

University College London

University Hospital Oslo

University of Aarhus

University of Luebeck

University of Sheffield

University of Tuebingen

Vrije Universiteit: Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patientenzorg

Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.